Quality of systematic reviews and meta-analyses in dermatology

Annapoorani Muthiah, Loch Kith Lee, John Koh, Ashly Liu, Aidan Tan
{"title":"Quality of systematic reviews and meta-analyses in dermatology","authors":"Annapoorani Muthiah,&nbsp;Loch Kith Lee,&nbsp;John Koh,&nbsp;Ashly Liu,&nbsp;Aidan Tan","doi":"10.1002/cesm.12056","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Although the number of published systematic reviews and meta-analyses in dermatology has increased over the past decade, their quality is unknown.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>The objective of this study was to determine the change in risk of bias, methodological quality and reporting quality of systematic reviews and meta-analyses in dermatology between 2010 and 2019.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a comparative study of systematic reviews and meta-analyses published in the 10 highest-ranked dermatology journals in 2010 and 2019. Studies were identified through electronic searches of MEDLINE, Embase, and eight other bibliographic databases. Risk of bias and methodological quality were assessed in duplicate with the risk of bias in systematic reviews (ROBIS) and A MeaSurement Tool to Assess systematic Reviews-2 (AMSTAR-2) tools, respectively, with the latter only applied to studies of interventions. Reporting quality was assessed with the Preferred Reporting Items of systematic reviews and Meta-Analyses (PRISMA) 2009 and PRISMA for abstracts (PRISMA-A) 2013 statements.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We included 27 systematic reviews and meta-analyses published in 2010 and 127 published in 2019. There was no evidence of a difference in the proportion of systematic reviews and meta-analyses at high/unclear risk of bias with ROBIS (Fisher's exact test = 1.00) or critically low methodological quality using AMSTAR-2 (Fisher's exact test = 0.456), between 2010 and 2019. There was evidence of a difference in proportion of PRISMA (<i>t</i>(26) = 2.7, <i>p</i> = 0.01), and very strong evidence of a difference in proportion of PRISMA-A (<i>t</i>(26) = 4.2, <i>p</i> &lt; 0.001) checklist items adequately reported between 2010 and 2019. The difference in mean proportion of PRISMA checklist items adequately reported was 3.6 items more (95% confidence interval [CI]: 1.8–5.4 items more) in 2019 (mean = 10.7 items, SD = 2.4 items) than in 2010 (mean = 7.1 items, SD = 2.9 items), and of PRISMA-A checklist items adequately reported was 1.1 items more (95% CI: 0.2–2.0 items more) in 2019 (mean = 5.6 items, SD = 1.5 items) than in 2010 (mean = 4.4 items, SD = 1.7 items)</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>No improvement was observed in the overall methodological quality of included systematic reviews and meta-analyses; however, there was strong evidence of improvement in the overall reporting quality.</p>\n </section>\n </div>","PeriodicalId":100286,"journal":{"name":"Cochrane Evidence Synthesis and Methods","volume":"2 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12056","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cochrane Evidence Synthesis and Methods","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cesm.12056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Although the number of published systematic reviews and meta-analyses in dermatology has increased over the past decade, their quality is unknown.

Objective

The objective of this study was to determine the change in risk of bias, methodological quality and reporting quality of systematic reviews and meta-analyses in dermatology between 2010 and 2019.

Methods

We conducted a comparative study of systematic reviews and meta-analyses published in the 10 highest-ranked dermatology journals in 2010 and 2019. Studies were identified through electronic searches of MEDLINE, Embase, and eight other bibliographic databases. Risk of bias and methodological quality were assessed in duplicate with the risk of bias in systematic reviews (ROBIS) and A MeaSurement Tool to Assess systematic Reviews-2 (AMSTAR-2) tools, respectively, with the latter only applied to studies of interventions. Reporting quality was assessed with the Preferred Reporting Items of systematic reviews and Meta-Analyses (PRISMA) 2009 and PRISMA for abstracts (PRISMA-A) 2013 statements.

Results

We included 27 systematic reviews and meta-analyses published in 2010 and 127 published in 2019. There was no evidence of a difference in the proportion of systematic reviews and meta-analyses at high/unclear risk of bias with ROBIS (Fisher's exact test = 1.00) or critically low methodological quality using AMSTAR-2 (Fisher's exact test = 0.456), between 2010 and 2019. There was evidence of a difference in proportion of PRISMA (t(26) = 2.7, p = 0.01), and very strong evidence of a difference in proportion of PRISMA-A (t(26) = 4.2, p < 0.001) checklist items adequately reported between 2010 and 2019. The difference in mean proportion of PRISMA checklist items adequately reported was 3.6 items more (95% confidence interval [CI]: 1.8–5.4 items more) in 2019 (mean = 10.7 items, SD = 2.4 items) than in 2010 (mean = 7.1 items, SD = 2.9 items), and of PRISMA-A checklist items adequately reported was 1.1 items more (95% CI: 0.2–2.0 items more) in 2019 (mean = 5.6 items, SD = 1.5 items) than in 2010 (mean = 4.4 items, SD = 1.7 items)

Conclusions

No improvement was observed in the overall methodological quality of included systematic reviews and meta-analyses; however, there was strong evidence of improvement in the overall reporting quality.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
皮肤病学系统综述和荟萃分析的质量
引言 尽管在过去十年中发表的皮肤病学系统综述和荟萃分析的数量有所增加,但其质量却不为人知。 目的 本研究旨在确定 2010 年至 2019 年间皮肤科系统综述和荟萃分析的偏倚风险、方法学质量和报告质量的变化。 方法 我们对 2010 年和 2019 年在 10 种排名最高的皮肤病学期刊上发表的系统综述和荟萃分析进行了比较研究。通过对 MEDLINE、Embase 和其他 8 个文献数据库进行电子检索,确定了相关研究。偏倚风险和方法学质量分别采用系统综述偏倚风险工具(ROBIS)和系统综述评估工具-2(AMSTAR-2)进行评估,后者仅适用于干预研究。报告质量采用 2009 年系统性综述和 Meta 分析首选报告项目 (PRISMA) 和 2013 年摘要首选报告项目 (PRISMA-A) 声明进行评估。 结果 我们纳入了 27 篇 2010 年发表的系统综述和荟萃分析,以及 127 篇 2019 年发表的系统综述和荟萃分析。2010年和2019年之间,没有证据表明使用ROBIS(费雪精确检验=1.00)进行的偏倚风险高/不明确的系统综述和荟萃分析的比例存在差异,也没有证据表明使用AMSTAR-2(费雪精确检验=0.456)进行的方法学质量极低的系统综述和荟萃分析的比例存在差异。有证据表明,2010 年和 2019 年之间,充分报告 PRISMA(t(26) = 2.7,p = 0.01)的比例存在差异,有非常有力的证据表明,充分报告 PRISMA-A (t(26) = 4.2,p < 0.001)核对表项目的比例存在差异。与 2010 年(平均 = 7.1 项,SD = 2.9 项)相比,2019 年(平均 = 10.7 项,SD = 2.4 项)充分报告的 PRISMA 核对表项目的平均比例多 3.6 项(95% 置信区间 [CI]:多 1.8-5.4 项),2019 年(平均 = 5.6 项,SD = 1.5 项)比 2010 年(平均 = 4.4 项,SD = 1.7 项)多 1.1 项(95% CI:多 0.2-2.0 项) 结论 未观察到纳入的系统综述和荟萃分析的总体方法学质量有所改善;但是,有强有力的证据表明总体报告质量有所改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Methodological and reporting quality of systematic and rapid reviews on human mpox and their utility during a public health emergency Issue Information “Interest-holders”: A new term to replace “stakeholders” in the context of health research and policy Empowering the future of evidence-based healthcare: The Cochrane Early Career Professionals Network Issue Information
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1